CD8A and neoplasm: Taken together, these results suggest that DMXAA, on top of UPs-4T1/EPB nanovaccine, results in more significant activation, maturation, and migration of the UPs-4T1/EPB-loaded DCs to DLN through stimulating the secretion of IFN-β and IL-12, enhancing CD8+ T cell responses, and enhancing CD8+ TIL infiltration in the tumor tissue, ultimately leading to complete tumor eradication in this model.